Gert Ossenkoppele Department of Hematology VU University Medical Center Biography Publications Institution JoVE Articles Gert Ossenkoppele has not added a biography. If you are Gert Ossenkoppele and would like to personalize this page please email our Author Liaison for assistance. Publications Minimal/measurable Residual Disease in AML: Consensus Document from ELN MRD Working Party Blood. Jan, 2018 | Pubmed ID: 29330221 The Interference of Genetic Associations in Establishing the Prognostic Value of the Immunophenotype in Acute Myeloid Leukemia Cytometry. Part B, Clinical Cytometry. Jan, 2018 | Pubmed ID: 28646564 Validation of and Proposals for Refinements of the WHO 2016 Classification for Myelodysplastic Syndromes American Journal of Hematology. Nov, 2017 | Pubmed ID: 28741674 Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference? Cancers. Jun, 2017 | Pubmed ID: 28665351 Single Cell Immune Profiling by Mass Cytometry of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Nilotinib Haematologica. Aug, 2017 | Pubmed ID: 28522574 Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase: ENEST1st Subanalysis Journal of Cancer Research and Clinical Oncology. Aug, 2017 | Pubmed ID: 28364360 Genomic Array As Compared to Karyotyping in Myelodysplastic Syndromes in a Prospective Clinical Trial Genes, Chromosomes & Cancer. Jul, 2017 | Pubmed ID: 28236351 Therapeutic Value of Clofarabine in Younger and Middle-aged (18-65 Years) Adults with Newly Diagnosed AML Blood. Mar, 2017 | Pubmed ID: 28049642 Implementation of Erythroid Lineage Analysis by Flow Cytometry in Diagnostic Models for Myelodysplastic Syndromes Haematologica. 02, 2017 | Pubmed ID: 27658438 MRD in AML: Does It Already Guide Therapy Decision-making? Hematology. American Society of Hematology. Education Program. Dec, 2016 | Pubmed ID: 27913502 Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2016 | Pubmed ID: 27006491 Prognostic Relevance of Morphological Classification Models for Myelodysplastic Syndromes in an Era of the Revised International Prognostic Scoring System European Journal of Cancer (Oxford, England : 1990). Mar, 2016 | Pubmed ID: 26798967 Risk Factors for Relapse After Allogeneic Transplantation in Acute Myeloid Leukemia Haematologica. Jan, 2016 | Pubmed ID: 26721801 Multiparameter Flow Cytometry is Instrumental to Distinguish Myelodysplastic Syndromes from Non-neoplastic Cytopenias European Journal of Cancer (Oxford, England : 1990). Feb, 2016 | Pubmed ID: 26720403 Primary Acute Myeloid Leukemia Cells with Overexpression of EVI-1 Are Sensitive to All-trans Retinoic Acid Blood. Jan, 2016 | Pubmed ID: 26582376 Chronic Myeloid Leukemia in the Netherlands: a Population-based Study on Incidence, Treatment, and Survival in 3585 Patients from 1989 to 2012 European Journal of Haematology. Aug, 2016 | Pubmed ID: 26519944 Application of Flow Cytometry for Myelodysplastic Syndromes: Pitfalls and Technical Considerations Cytometry. Part B, Clinical Cytometry. Jul, 2016 | Pubmed ID: 26517178 Multifactorial Resistance to Aminopeptidase Inhibitor Prodrug CHR2863 in Myeloid Leukemia Cells: Down-regulation of Carboxylesterase 1, Drug Sequestration in Lipid Droplets and Pro-survival Activation ERK/Akt/mTOR Oncotarget. Feb, 2016 | Pubmed ID: 26496029 Post-remission Treatment with Allogeneic Stem Cell Transplantation in Patients Aged 60 Years and Older with Acute Myeloid Leukaemia: a Time-dependent Analysis The Lancet. Haematology. Oct, 2015 | Pubmed ID: 26686044 A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation PloS One. 2015 | Pubmed ID: 26252775 Differential Capacity of Human Interleukin-4 and Interferon-α Monocyte-derived Dendritic Cells for Cross-presentation of Free Versus Cell-associated Antigen Cancer Immunology, Immunotherapy : CII. Nov, 2015 | Pubmed ID: 26216454 Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/refractory Acute Myeloid Leukemia: Analysis of 1,892 Patients from HOVON/SAKK and SWOG Haematologica. Oct, 2015 | Pubmed ID: 26160876 Regulatory T Cells and Progenitor B Cells Are Independent Prognostic Predictors in Lower Risk Myelodysplastic Syndromes Haematologica. Jun, 2015 | Pubmed ID: 25749828 Immunophenotyping for Diagnosis and Prognosis in MDS: Ready for General Application? Best Practice & Research. Clinical Haematology. Mar, 2015 | Pubmed ID: 25659726 Tyrosine Kinase Inhibitors Improve Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Haematologica. Mar, 2015 | Pubmed ID: 25527562 How I Treat the Older Patient with Acute Myeloid Leukemia Blood. Jan, 2015 | Pubmed ID: 25515963 Resistance Prediction in AML: Analysis of 4601 Patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center Leukemia. Feb, 2015 | Pubmed ID: 25113226 Loading of Skin Dendritic Cells with Apoptotic Bleb-derived Antigens for the Induction of Tumor-directed Immunity Oncoimmunology. 2014 | Pubmed ID: 25610730 MRD in AML: It is Time to Change the Definition of Remission Best Practice & Research. Clinical Haematology. Sep-Dec, 2014 | Pubmed ID: 25455276 Genomic Amplification of MYC As Double Minutes in a Patient with APL-like Leukemia Molecular Cytogenetics. 2014 | Pubmed ID: 25392715 Leukemic Stem Cell Frequency: a Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia PloS One. 2014 | Pubmed ID: 25244440 BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-positive Leukemia Cancer Cell. Sep, 2014 | Pubmed ID: 25132497 High Class II-associated Invariant Chain Peptide Expression on Residual Leukemic Cells is Associated with Increased Relapse Risk in Acute Myeloid Leukemia Leukemia Research. Jun, 2014 | Pubmed ID: 24731748 Safety and Efficacy of Switching to Nilotinib 400 Mg Twice Daily for Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Response or Failure on Front-line Imatinib or Nilotinib 300 Mg Twice Daily Haematologica. Jul, 2014 | Pubmed ID: 24532039 Attenuation of MicroRNA-126 Expression That Drives CD34+38- Stem/progenitor Cells in Acute Myeloid Leukemia Leads to Tumor Eradication Cancer Research. Apr, 2014 | Pubmed ID: 24477595 Absence of Aberrant Myeloid Progenitors by Flow Cytometry is Associated with Favorable Response to Azacitidine in Higher Risk Myelodysplastic Syndromes Cytometry. Part B, Clinical Cytometry. May, 2014 | Pubmed ID: 24474614 Absence of Aberrant Myeloid Progenitors by Flow Cytometry is Associated with Favorable Response to Azacitidine in Higher Risk Myelodysplastic Syndromes Cytometry. Part B, Clinical Cytometry. Jan, 2014 | Pubmed ID: 24431028 Positioning of Aminopeptidase Inhibitors in Next Generation Cancer Therapy Amino Acids. Apr, 2014 | Pubmed ID: 24385243 Apoptotic Blebs from Leukemic Cells As a Preferred Source of Tumor-associated Antigen for Dendritic Cell-based Vaccines Cancer Immunology, Immunotherapy : CII. Apr, 2014 | Pubmed ID: 24384837 How to Assess Minimal Residual Disease in Pediatric and Adult Acute Myeloid Leukemia? Translational Pediatrics. Apr, 2013 | Pubmed ID: 26835296 Normal Hematopoietic Stem Cells Within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level Than Co-existing Leukemic Stem Cells PloS One. 2013 | Pubmed ID: 24244383 Procedures for the Expansion of CD14(+) Precursors from Acute Myeloid Leukemic Cells to Facilitate Dendritic Cell-based Immunotherapy Immunotherapy. Nov, 2013 | Pubmed ID: 24188673 Targeting the Acute Myeloid Leukemic Stem Cell Compartment by Enhancing Tumor Cell-based Vaccines Immunotherapy. Aug, 2013 | Pubmed ID: 23902555 Imatinib Discontinuation in Chronic Phase Myeloid Leukaemia Patients in Sustained Complete Molecular Response: a Randomised Trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON) European Journal of Cancer (Oxford, England : 1990). Oct, 2013 | Pubmed ID: 23876833 Priming of PRAME- and WT1-specific CD8T Cells in Healthy Donors but Not in AML Patients in Complete Remission: Implications for Immunotherapy Oncoimmunology. Apr, 2013 | Pubmed ID: 23734332 High-dose Imatinib Versus High-dose Imatinib in Combination with Intermediate-dose Cytarabine in Patients with First Chronic Phase Myeloid Leukemia: a Randomized Phase III Trial of the Dutch-Belgian HOVON Study Group Annals of Hematology. Aug, 2013 | Pubmed ID: 23572137 MRD in AML: Time for Redefinition of CR? Blood. Mar, 2013 | Pubmed ID: 23520326 Autologous Stem Cell Transplantation in Elderly Acute Myeloid Leukemia Mediterranean Journal of Hematology and Infectious Diseases. 2013 | Pubmed ID: 23505606 MicroRNA Profiling Can Classify Acute Leukemias of Ambiguous Lineage As Either Acute Myeloid Leukemia or Acute Lymphoid Leukemia Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2013 | Pubmed ID: 23444217 Significance of FAB Subclassification of "acute Myeloid Leukemia, NOS" in the 2008 WHO Classification: Analysis of 5848 Newly Diagnosed Patients Blood. Mar, 2013 | Pubmed ID: 23325837 A Threshold of 10% for Myeloperoxidase by Flow Cytometry is Valid to Classify Acute Leukemia of Ambiguous and Myeloid Origin Cytometry. Part B, Clinical Cytometry. Mar, 2013 | Pubmed ID: 23325578 Rationale for the Clinical Application of Flow Cytometry in Patients with Myelodysplastic Syndromes: Position Paper of an International Consortium and the European LeukemiaNet Working Group Leukemia & Lymphoma. Mar, 2013 | Pubmed ID: 22916713 Addition of Bevacizumab to Chemotherapy in Acute Myeloid Leukemia at Older Age: a Randomized Phase 2 Trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK) Blood. Dec, 2012 | Pubmed ID: 23047822 Tumor Immune Escape in Acute Myeloid Leukemia: Class II-associated Invariant Chain Peptide Expression As Result of Deficient Antigen Presentation Oncoimmunology. Mar, 2012 | Pubmed ID: 22720245 Promiscuous Binding of Invariant Chain-derived CLIP Peptide to Distinct HLA-I Molecules Revealed in Leukemic Cells PloS One. 2012 | Pubmed ID: 22563374 Towards a Joint Definition of European Hematology Haematologica. May, 2012 | Pubmed ID: 22556351 Azacitidine Differentially Affects CD4(pos) T-cell Polarization in Vitro and in Vivo in High Risk Myelodysplastic Syndromes Leukemia Research. Jul, 2012 | Pubmed ID: 22503132 Class II-associated Invariant Chain Peptide Expression Represents a Novel Parameter for Flow Cytometric Detection of Acute Promyelocytic Leukemia The American Journal of Pathology. Nov, 2011 | Pubmed ID: 21907692 Prognostic Impact of White Blood Cell Count in Intermediate Risk Acute Myeloid Leukemia: Relevance of Mutated NPM1 and FLT3-ITD Haematologica. Sep, 2011 | Pubmed ID: 21606167 Chronic Myeloid Leukemia Lysate-loaded Dendritic Cells Induce T-cell Responses Towards Leukemia Progenitor Cells Immunotherapy. Apr, 2011 | Pubmed ID: 21463196 Review of the Relevance of Aberrant Antigen Expression by Flow Cytometry in Myeloid Neoplasms British Journal of Haematology. May, 2011 | Pubmed ID: 21385170 Challenging Diagnosis in a Patient with Clear Lymphoid Immunohistochemical Features and Myeloid Morphology: Mixed Phenotype Acute Leukemia with Erythrophagocytosis Leukemia Research. May, 2011 | Pubmed ID: 21334744 Absence of Class II-associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-reactive CD4+ T Cells Cancer Research. Apr, 2011 | Pubmed ID: 21310823 Targeting Toll-like Receptor 7/8 Enhances Uptake of Apoptotic Leukemic Cells by Monocyte-derived Dendritic Cells but Interferes with Subsequent Cytokine-induced Maturation Cancer Immunology, Immunotherapy : CII. Jan, 2011 | Pubmed ID: 20859626 Alternative Ii-independent Antigen-processing Pathway in Leukemic Blasts Involves TAP-dependent Peptide Loading of HLA Class II Complexes Cancer Immunology, Immunotherapy : CII. Dec, 2010 | Pubmed ID: 20820776 Impaired Antigen Presentation in Neoplasia: Basic Mechanisms and Implications for Acute Myeloid Leukemia Immunotherapy. Jan, 2010 | Pubmed ID: 20635891 Recent Advances in Antigen-loaded Dendritic Cell-based Strategies for Treatment of Minimal Residual Disease in Acute Myeloid Leukemia Immunotherapy. Jan, 2010 | Pubmed ID: 20635890 Methylation Patterns in CD34 Positive Chronic Myeloid Leukemia Blast Crisis Cells Haematologica. Jun, 2010 | Pubmed ID: 20421276 Molecular Targeted Therapies for Diffuse Large B-cell Lymphoma Based on Apoptosis Profiles The Journal of Pathology. Apr, 2010 | Pubmed ID: 20087881 Aberrant Immunophenotype of Blasts in Myelodysplastic Syndromes is a Clinically Relevant Biomarker in Predicting Response to Growth Factor Treatment Blood. Mar, 2010 | Pubmed ID: 20038788 Class II-associated Invariant Chain Peptide Down-modulation Enhances the Immunogenicity of Myeloid Leukemic Blasts Resulting in Increased CD4+ T-cell Responses Haematologica. Mar, 2010 | Pubmed ID: 19903675 A 51-year-old Male CML Patient with Progressive Hearing Loss, Confusion, Ataxia, and Aphasia During Imatinib Treatment American Journal of Hematology. Oct, 2009 | Pubmed ID: 19658186 Standardization of Flow Cytometry in Myelodysplastic Syndromes: Report from the First European LeukemiaNet Working Conference on Flow Cytometry in Myelodysplastic Syndromes Haematologica. Aug, 2009 | Pubmed ID: 19546437 Interleukin-2 Receptor Alpha-chain (CD25) Expression on Leukaemic Blasts is Predictive for Outcome and Level of Residual Disease in AML European Journal of Cancer (Oxford, England : 1990). Jun, 2009 | Pubmed ID: 19321337 Immune Mediated Autologous Cytotoxicity Against Hematopoietic Precursor Cells in Patients with Myelodysplastic Syndrome Haematologica. Apr, 2009 | Pubmed ID: 19229054 Correlation of Minimal Residual Disease Cell Frequency with Molecular Genotype in Patients with Acute Myeloid Leukemia Haematologica. Jan, 2009 | Pubmed ID: 19042917 Identification of a Small Subpopulation of Candidate Leukemia-initiating Cells in the Side Population of Patients with Acute Myeloid Leukemia Stem Cells (Dayton, Ohio). Dec, 2008 | Pubmed ID: 19096043 Concurrent Methylation of Promoters from Tumor Associated Genes Predicts Outcome in Acute Myeloid Leukemia Leukemia & Lymphoma. Jun, 2008 | Pubmed ID: 18569637 Positive Selection for CD90 As a Purging Option in Acute Myeloid Leukemia Stem Cell Transplants Cytometry. Part B, Clinical Cytometry. Jan, 2008 | Pubmed ID: 18061946 Identification of Distinct Prognostic Subgroups in Low- and Intermediate-1-risk Myelodysplastic Syndromes by Flow Cytometry Blood. Feb, 2008 | Pubmed ID: 17971483 Chemotherapeutic Treatment of Bone Marrow Stromal Cells Strongly Affects Their Protective Effect on Acute Myeloid Leukemia Cell Survival Leukemia & Lymphoma. Jan, 2008 | Pubmed ID: 17926185 Small-molecule XIAP Antagonist Restores Caspase-9 Mediated Apoptosis in XIAP-positive Diffuse Large B-cell Lymphoma Cells Blood. Jan, 2008 | Pubmed ID: 17916749 New Approaches for the Detection of Minimal Residual Disease in Acute Myeloid Leukemia Current Hematologic Malignancy Reports. May, 2007 | Pubmed ID: 20425359 Inhibition of the Intrinsic Apoptosis Pathway Downstream of Caspase-9 Activation Causes Chemotherapy Resistance in Diffuse Large B-cell Lymphoma Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Dec, 2007 | Pubmed ID: 18056177 Activated Intrinsic Apoptosis Pathway is a Key Related Prognostic Parameter in Acute Myeloid Leukemia Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Apr, 2007 | Pubmed ID: 17401010 CD34-related Coexpression of MDR1 and BCRP Indicates a Clinically Resistant Phenotype in Patients with Acute Myeloid Leukemia (AML) of Older Age Annals of Hematology. May, 2007 | Pubmed ID: 17340137 Leukemia-specific T-cell Reactivity Induced by Leukemic Dendritic Cells is Augmented by 4-1BB Targeting Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2007 | Pubmed ID: 17170077 Autologous Hematopoietic Stem Cell Transplantation in Refractory Celiac Disease with Aberrant T Cells Blood. Mar, 2007 | Pubmed ID: 17068146 Feasibility of Clinical Dendritic Cell Vaccination in Acute Myeloid Leukemia Immunobiology. 2006 | Pubmed ID: 16920506 Principles of Dendritic Cell-based Immunotherapy in Myeloid Leukemia Immunobiology. 2006 | Pubmed ID: 16920505 Leukemia-derived Dendritic Cells: Towards Clinical Vaccination Protocols in Acute Myeloid Leukemia Haematologica. Mar, 2006 | Pubmed ID: 16531258 High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2005 | Pubmed ID: 16166428 Employing the Immunological Synapse in AML: Development of Leukemic Dendritic Cells for Active Specific Immunization Immunobiology. 2005 | Pubmed ID: 16164032 Immunologic Purging of Autologous Peripheral Blood Stem Cell Products Based on CD34 and CD133 Expression Can Be Effectively and Safely Applied in Half of the Acute Myeloid Leukemia Patients Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2005 | Pubmed ID: 16000576 Quantification of T-cell-mediated Apoptosis in Heterogeneous Leukemia Populations Using Four-color Multiparameter Flow Cytometry Cytometry. Part A : the Journal of the International Society for Analytical Cytology. Jul, 2005 | Pubmed ID: 15895438 Minimal Residual Disease in Acute Myeloid Leukemia is Predicted by an Apoptosis-resistant Protein Profile at Diagnosis Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2005 | Pubmed ID: 15814631 Purging of Peripheral Blood Stem Cell Transplants in AML: a Predictive Model Based on Minimal Residual Disease Burden Experimental Hematology. Jan, 2005 | Pubmed ID: 15661405 Antibody-targeted Therapy: a Paradigm of Innovative Treatment Strategies in Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Current Opinion in Hematology. Nov, 2004 | Pubmed ID: 15548997 Class II-associated Invariant Chain Peptide Expression on Myeloid Leukemic Blasts Predicts Poor Clinical Outcome Cancer Research. Aug, 2004 | Pubmed ID: 15313888 The Value of Fludarabine in Addition to ARA-C and G-CSF in the Treatment of Patients with High-risk Myelodysplastic Syndromes and AML in Elderly Patients Blood. Apr, 2004 | Pubmed ID: 15070662 Emerging Antibody-targeted Therapy in Leukemia and Lymphoma: Current Concepts and Clinical Implications Anti-cancer Drugs. Mar, 2004 | Pubmed ID: 15014351 Assessment of the Normal or Leukemic Nature of CD34+ Cells in Acute Myeloid Leukemia with Low Percentages of CD34 Cells Haematologica. Sep, 2003 | Pubmed ID: 12969806 Novel Multiparameter Flow Cytometry Assay Using Syto16 for the Simultaneous Detection of Early Apoptosis and Apoptosis-corrected P-glycoprotein Function in Clinical Samples Cytometry. Part B, Clinical Cytometry. Sep, 2003 | Pubmed ID: 12949955 Differences Between the CD34+ and CD34- Blast Compartments in Apoptosis Resistance in Acute Myeloid Leukemia Haematologica. May, 2003 | Pubmed ID: 12745269 ALK-negative Systemic Anaplastic Large Cell Lymphoma: Differential Diagnostic and Prognostic Aspects--a Review The Journal of Pathology. May, 2003 | Pubmed ID: 12692835 Serum-free Generation of Antigen Presenting Cells from Acute Myeloid Leukaemic Blasts for Active Specific Immunisation Cancer Immunology, Immunotherapy : CII. Jul, 2003 | Pubmed ID: 12690520 Function of the ABC Transporters, P-glycoprotein, Multidrug Resistance Protein and Breast Cancer Resistance Protein, in Minimal Residual Disease in Acute Myeloid Leukemia Haematologica. Feb, 2003 | Pubmed ID: 12604403 Expression Levels of Apoptosis-related Proteins Predict Clinical Outcome in Anaplastic Large Cell Lymphoma Blood. Jun, 2002 | Pubmed ID: 12036886 Omfattende protokol til prøven og proces knoglemarven til at måle målbare Residual sygdom og Leukemic stamceller i akut Myeloid leukæmi Jacqueline Cloos*1,2, Jeffrey R. Harris*3, Jeroen J.W.M. Janssen1, Angele Kelder1, F. Huang3, Gerrit Sijm1, Maike Vonk1, Alexander N. Snel1, Jennifer R. Scheick1, Willemijn J. Scholten1, Jannemieke Carbaat-Ham1, Dennis Veldhuizen1, Diana Hanekamp1, Yvonne J.M. Oussoren-Brockhoff1, Gertjan J.L. Kaspers2,4, Gerrit J. Schuurhuis1, A. Kate Sasser3, Gert Ossenkoppele1 1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology JoVE 56386 Cancer Research
Omfattende protokol til prøven og proces knoglemarven til at måle målbare Residual sygdom og Leukemic stamceller i akut Myeloid leukæmi Jacqueline Cloos*1,2, Jeffrey R. Harris*3, Jeroen J.W.M. Janssen1, Angele Kelder1, F. Huang3, Gerrit Sijm1, Maike Vonk1, Alexander N. Snel1, Jennifer R. Scheick1, Willemijn J. Scholten1, Jannemieke Carbaat-Ham1, Dennis Veldhuizen1, Diana Hanekamp1, Yvonne J.M. Oussoren-Brockhoff1, Gertjan J.L. Kaspers2,4, Gerrit J. Schuurhuis1, A. Kate Sasser3, Gert Ossenkoppele1 1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology JoVE 56386 Cancer Research
